



Cases from the Clinic: Focus on Endometrial Cancer

Clinical Brief #1 – Treatment of Advanced EC

References

Tweet 2 References:

Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. *N Engl J Med*. 2023;388:2159-2170. doi:10.1056/NEJMoa2302312

Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. *N Engl J Med*. 2023;388:2145-2158. doi:10.1056/NEJMoa2216334

Additional References:

Disis ML, Adams SF, Bajpai J, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. *J Immunother Cancer*. 2023;11(6):e006624. doi:10.1136/jitc-2022-006624

Makker V, Aghajanian C, Cohn AL, et al. A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. *J Clin Oncol*. 2023;41(5):974-979. doi:10.1200/JCO.22.01021

Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. *J Clin Oncol*. 2020;38(26):2981-2992. doi:10.1200/JCO.19.02627

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Uterine Neoplasms (v2.2023). Updated April 28, 2023. Accessed May 8, 2023. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. *J Immunother Cancer*. 2022;10(1):e003777. doi:10.1136/jitc-2021-003777

Oaknin A, Pothuri B, Gilbert L, et al. Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. *J Clin Oncol*. 2022;40(16_suppl):5509-5509. doi:10.1200/JCO.2022.40.16_suppl.5509

O'Malley D, Bariani GM, Cassier PA, et al. 546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158. *Ann Oncol*. 2022;33:S796-S797. doi:10.1016/j.annonc.2022.07.674



O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. *J Clin Oncol*. 2022;40(7):752-761. doi:10.1200/JCO.21.01874

Glossary

≥1L, first-line and subsequent
1L, first-line
A, advanced
A/R, advanced/recurrent
AE, adverse event
Chemo, chemotherapy
CI, confidence interval
dMMR, mismatch repair deficient
DOR, duration of response
EC, endometrial cancer
HR, hazard ratio
IO, immunotherapy
m, median
MSI-H, microsatellite instability high
MSS, microsatellite stable
NR, not reached
ORR, objective response rate
OS, overall survival
PFS, progression-free survival
pMMR, mismatch repair proficient
PPE, palmar-plantar erythrodysesthesia
R, recurrent
SOC, standard of care
TMB-H, tumor mutational burden high
w/, with